公开(公告)号：US09051348B2

公开(公告)日：2015-06-09

申请号：US14040738

申请日：2013-09-30

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Liping Bai ,  Hang Dong ,  Kam Wai Wong ,  Zhihong Jiang ,  Hua Zhou

IPC: C07J17/00

CPC classification number: C07J17/005

Abstract: The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.

Abstract translation: 本发明涉及一种衍生自人参皂苷Rh2的新型化合物，其制备方法及其在治疗癌症中的应用。

公开(公告)号：US11648258B2

公开(公告)日：2023-05-16

申请号：US14399960

申请日：2013-05-09

Applicant: The Hong Kong University Of Science And Technology ,  Hong Kong Baptist University ,  Macau University Of Science And Technology

Inventor： Chun Liang ,  Zhihong Jiang ,  Ziyi Wang ,  Zhiling Yu ,  Jingrong Wang ,  Liping Bai

IPC: A61K31/7048 ,  A61K31/585 ,  G01N33/50 ,  G01N33/574

CPC classification number: A61K31/7048 ,  A61K31/585 ,  G01N33/5011 ,  G01N33/5044 ,  G01N33/574 ,  G01N2458/00 ,  G01N2500/10

Abstract: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.

公开(公告)号：US09273088B2

公开(公告)日：2016-03-01

申请号：US14055883

申请日：2013-10-17

Applicant: Macau University of Science and Technology

Inventor： Jingrong Wang ,  Pei Luo ,  Hua Zhou ,  Wai In Chan ,  Liang Liu ,  Zhihong Jiang

IPC: A61K31/704 ,  C07J17/00

CPC classification number: C07J17/005 ,  A61K31/704

Abstract: The present invention provides novel ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury.

Abstract translation: 本发明提供新型人参皂苷衍生物化合物及其在防止缺血/再灌注损伤中的应用。

公开(公告)号：US09955676B2

公开(公告)日：2018-05-01

申请号：US14620141

申请日：2015-02-11

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Ting Li ,  Kam Wai Wong ,  Zhihong Jiang ,  Hua Zhou

IPC: A01K67/027 ,  C12N15/00 ,  A61K49/00 ,  G01N33/573 ,  A61K31/70 ,  G01N33/574

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0368 ,  A61K49/0008 ,  G01N33/573 ,  G01N33/574 ,  G01N2333/91215 ,  G01N2800/102 ,  G01N2800/44

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.